Evidence map›Paper›PMID 40108519›Full record

ArticleBMC infectious diseases2025

Evaluation of strongyloidiasis prevalence in immunocompromised patients referred to hospitals: a case study of Iran's capital.

Zahra Arab-Mazar, Tahereh Kanani, Mahdi Toulabi, Arian Karimi Rouzbahani, Shirzad Fallahi, Anahita Behzadi, Maysam Yousefi, Seyyed Javad Seyyed Tabaei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zahra Arab-MazarInfectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Tahereh KananiStudent Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.
Mahdi ToulabiStudent Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.
Arian Karimi RouzbahaniStudent Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.
Shirzad FallahiHepatitis Research Center, Department of Medical Parasitology and Mycology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Anahita BehzadiHealth Services Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Maysam YousefiResearch Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran. myousefi@kmu.ac.ir.
Seyyed Javad Seyyed TabaeiDepartment of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Seyyedtabaei@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStrongyloidiasis is a parasitic disease commonly caused by S. stercoralis. It can lead to serious consequences in immunocompromised patients. This study aimed to investigate the prevalence of S. stercoralis infection in immunocompromised patients referred to selected hospitals. METHODS AND MATERIALS: This was a cross-sectional study in which demographic information, including age, sex, occupation, place of residence, and type of underlying disease, was collected from patients with cancer or who were treated with high doses of corticosteroids for rheumatic diseases. Serum immunoglobulin G (IgG) antibodies against S. stercoralis were measured via enzyme-linked immunosorbent assay (ELISA). For patients with positive antibody tests, stool culture was performed, and the data were analyzed with SPSS software ver. 25.

resultsThere were included 93 patients in this study, in 11.8% there was administered high doses of corticosteroids due to rheumatic disease and 88.2% had cancer. S. stercoralis-IgG ELISA was positive in 30 patients (32.3%). There was a significant association between the type of disease and a positive IgG antibody test (P ≤ 0.015). Among seropositive patients, only one patient (3.3%) was positive in the stool culture. There was a significant association between the IgG antibody test score and occupation (P ≤ 0.002). Positive IgG antibodies were most common among employees (75%).

conclusionAlthough positive S. stercoralis-IgG antibody tests are common among immunocompromised patients, stool culture results are negative for most seropositive patients, indicating previous infections.

Indexed as

Immunocompromised HostStrongyloides stercoralisStrongyloidiasisAdolescentAdultAgedAged, 80 and overAnimalsAntibodies, HelminthCross-Sectional StudiesEnzyme-Linked Immunosorbent AssayFecesFemaleHospitalsHumansImmunoglobulin GAntibodies, HelminthImmunoglobulin GCancerCorticosteroidsImmunodeficiencyRheumatic diseaseStrongyloides StercoralisStrongyloidiasis

Identifiers

PMID40108519
PMCPMC11921683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.